INR (International Normalized Ratio) Calculator

Calculate and interpret INR values for warfarin monitoring. Essential tool for anticoagulation therapy management and bleeding risk assessment.

Direct INR Input
Calculate from PT
INR
Enter measured International Normalized Ratio value
0.5 2.5 10.0
Selecting an indication provides specific therapeutic range guidance
Calculating...

Understanding INR (International Normalized Ratio)

The International Normalized Ratio (INR) is a standardized number that represents the prothrombin time ratio. It's used to monitor the effectiveness of blood-thinning medications like warfarin, ensuring that blood clotting is within a safe and therapeutic range.

Clinical Importance: INR standardizes prothrombin time results across different laboratories and reagents, allowing for consistent monitoring of oral anticoagulant therapy. Maintaining INR within the therapeutic range is critical to prevent both thrombotic events (if too low) and bleeding complications (if too high).

INR Calculation Formula

INR Calculation Formula:
INR = (Patient PT / Control PT) ISI

Where:

  • Patient PT: Patient's prothrombin time in seconds
  • Control PT: Laboratory's mean normal prothrombin time in seconds
  • ISI: International Sensitivity Index of the thromboplastin reagent used
INR Range Classification Clinical Significance Typical Action
< 1.5 Subtherapeutic Increased risk of clotting May increase warfarin dose
1.5 - 2.0 Low therapeutic Marginally effective for some indications Consider dose adjustment
2.0 - 3.0 Therapeutic (Standard) Optimal for most indications Maintain current dose
3.0 - 3.5 High therapeutic Therapeutic for some high-risk conditions Monitor closely, may need adjustment
3.5 - 5.0 Supratherapeutic Increased bleeding risk Consider reducing dose or holding
> 5.0 High bleeding risk Significant bleeding risk May require vitamin K or hospitalization

Therapeutic INR Ranges by Clinical Indication

Clinical Indication Target INR Range Duration of Therapy Clinical Notes
Atrial Fibrillation 2.0 - 3.0 Long-term (often lifelong) Stroke prevention in non-valvular AF
DVT / PE Treatment 2.0 - 3.0 3-6 months (minimum) Initial treatment of venous thromboembolism
Mechanical Heart Valve 2.5 - 3.5 or 3.0 - 4.0 Lifelong Depends on valve type and position
Bioprosthetic Valve 2.0 - 3.0 3-6 months Temporary therapy post-implantation
Recurrent DVT/PE 2.0 - 3.0 Indefinite For patients with recurrent events
Antiphospholipid Syndrome 2.0 - 3.0 or 3.0 - 4.0 Indefinite Higher target for arterial thrombosis

Factors Affecting INR

1

Dietary Vitamin K: Vitamin K intake from green leafy vegetables (kale, spinach, broccoli) can antagonize warfarin and lower INR. Consistent vitamin K intake is important for stable INR control.

2

Medication Interactions: Many medications affect warfarin metabolism including antibiotics, antifungals, antiplatelets, NSAIDs, and supplements like coenzyme Q10 or ginkgo biloba.

3

Alcohol Consumption: Acute alcohol intake can increase INR, while chronic alcohol use may decrease warfarin metabolism and increase bleeding risk.

4

Liver Function: Liver disease affects production of clotting factors and warfarin metabolism, often requiring lower doses and more frequent monitoring.

Clinical Note: INR monitoring requires consideration of the patient's clinical context. A single INR value should be interpreted in light of the patient's history, recent dose changes, dietary intake, medication changes, and any signs of bleeding or thrombosis.

Frequently Asked Questions

Prothrombin time results vary between laboratories due to differences in reagents and equipment. The INR standardizes PT results by factoring in the International Sensitivity Index (ISI) of the thromboplastin reagent used. This allows for consistent monitoring and dosing decisions regardless of where the test is performed.

  • Initial stabilization: Daily or every 2-3 days until stable
  • Stable therapy: Every 4-6 weeks
  • After dose change: Within 5-7 days
  • With illness, diet change, or new medications: Within 3-7 days
  • Point-of-care testing: Can be done more frequently if needed

For INR 4.0-10.0 without bleeding: Hold warfarin and consider oral vitamin K (1-2.5 mg).
For INR >10.0 without bleeding: Hold warfarin and give oral vitamin K (2.5-5 mg).
For serious bleeding at any elevated INR: Hold warfarin, give vitamin K 10 mg IV slowly, and consider prothrombin complex concentrate or fresh frozen plasma.
Always consult your healthcare provider for personalized advice.

Switching between warfarin and DOACs (like apixaban, rivaroxaban, dabigatran) requires careful management:
  • Warfarin to DOAC: Start DOAC when INR < 2.0
  • DOAC to warfarin: Overlap until INR therapeutic (may take 5-10 days)
  • Bridge with heparin/LMWH: Often needed when switching for mechanical valves
Always switch under medical supervision with appropriate monitoring.

Time in Therapeutic Range (TTR) is the percentage of time a patient's INR remains within their target range. Higher TTR is associated with:
  • Reduced risk of stroke and systemic embolism
  • Reduced major bleeding events
  • Lower all-cause mortality
A TTR of >70% is considered excellent control. TTR can be improved through patient education, more frequent monitoring, and dedicated anticoagulation clinics.